HALO250417C65000
- 0.01
- -0.02-66.67%
Halozyme Therapeutics Newsroom
38% Of This Halozyme Therapeutics Insider's Holdings Were Sold
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
Peering Into Halozyme Therapeutics's Recent Short Interest
Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx
Halozyme Says European Commission Approves Darzalex Co-Formulated With Enhanze to Treat Multiple Myeloma
Express News | European Commission Approved Subcutaneous Darzalex® (Daratumumab)-Based Quadruplet Regimen for the Treatment of Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
European Commission Approved Subcutaneous DARZALEX (Daratumumab)-based Quadruplet Regimen for the Treatment of Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
Morgan Stanley Lists 'Attractive' Small-cap Stocks With Positive ROE and Momentum
Johnson & Johnson's Janssen Says Subcutaneous Rybrevant Approved for 2 Indications in EU
Halozyme Therapeutics Announced That Janssen-Cilag International NV, A J&J Company, Has Received European Commission Marketing Authorization Of The Subcutaneous Formulation Of RYBREVANT, In Combination With LAZCLUZE, For The First-Line Treatment Of...
Express News | European Commission Approves Subcutaneous Rybrevant® (Amivantamab) Co-Formulated With Enhanze® for the Treatment of Patients With Advanced Egfr-Mutated Non-Small Cell Lung Cancer
Russell 2000 Stumbles Nearly 10% in Q1 – How Biggest IWM ETF Holdings Fared
Express News | Merck: FDA Has Set Pdufa Date of Sept 23
Express News | Merck Exec Says Hopes to Launch Subcutaneous Keytruda on Oct 1, Sees Peak Adoption About 18-24 Months After Approval - Interview
Express News | Merck: Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Shows Noninferior Pharmacokinetics Vs IV Keytruda in 3475a-D77 Trial
Express News | Merck: Applications for Subcutaneous Pembrolizumab Are Under Review in U.S. & Europe
Express News | Merck Exec Says Will Launch Subcutaneous Keytruda at Risk if Halozyme Patent Dispute Not Resolved yet - Interview
Should You Be Adding Halozyme Therapeutics (NASDAQ:HALO) To Your Watchlist Today?
Artisan Small Cap Fund Reduced Its Stake in Halozyme Therapeutics (HALO). Here's Why
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $67